Apart from its direct effect on tumorigenesis, we have demonstrated that TLR2 mediates breast cancer resistance to doxorubicin and other drugs, inducing immunogenic cell death (ICD) and the release of DAMPs that activate TLR2 signaling in cancer cells, thereby enhancing their survival [29]. The gene discussed is TLR2; the disease is breast cancer.